文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19所致呼吸衰竭患者的吸气气道阻力

Inspiratory Airway Resistance in Respiratory Failure Due to COVID-19.
PubMed 文献 · Crit Care Explor · 2022-03-25
一句话结论COVID-19相关ARDS机械通气患者吸气气道阻力中位数为12 cm H2O/L/s,属正常至轻度升高,与阻塞性气道疾病史、疾病严重度生物标志物及90天生存均无关。

本研究为观察性队列(便利样本),在3个社区ICU纳入55例COVID-19机械通气患者,于容量控制通气下用流量-时间与压力-时间曲线测量吸气气道阻力。结果中位吸气阻力为12 cm H2O/L/s(四分位间距10-16),有哮喘或慢性阻塞性肺疾病史者与无阻塞性气道疾病史者相比无显著差异(中位12.5 vs 12 cm H2O/L/s,p=0.66)。吸气阻力>12 cm H2O/L/s者90天生存率为68%,<12 cm H2O/L/s者为60%(p=0.58)。吸气阻力与C反应蛋白、铁蛋白、PaO2/FiO2比值及静态顺应性均无相关性。结论认为COVID-19相关ARDS患者的吸气气道阻力正常至轻度升高,不依赖于阻塞性气道疾病史,不与疾病严重度生物标志物相关,也不能预测死亡。

要点

  • 55例COVID-19机械通气患者吸气气道阻力中位数为12 cm H2O/L/s(四分位间距10-16),总体正常至轻度升高。
  • 有哮喘或COPD史者与无阻塞性气道疾病史者吸气阻力无显著差异(中位12.5 vs 12 cm H2O/L/s,p=0.66)。
  • 吸气阻力>12 cm H2O/L/s者90天生存率68%,<12 cm H2O/L/s者为60%,差异无统计学意义(p=0.58)。
  • 吸气阻力与C反应蛋白、铁蛋白、PaO2/FiO2比值及静态顺应性均无相关性。

适用人群与场景

  • 3个社区ICU中55例COVID-19机械通气患者,测量在容量控制通气下进行。

研究设计与关键结果

  • 研究类型为观察性队列(便利样本),共55例COVID-19机械通气患者,在3个社区ICU进行。
  • 吸气气道阻力中位数为12 cm H2O/L/s(四分位间距10-16)。
  • 有哮喘或慢性阻塞性肺疾病史者与无阻塞性气道疾病史者吸气阻力无显著差异(中位12.5 vs 12 cm H2O/L/s,p=0.66)。
  • 吸气阻力>12 cm H2O/L/s者90天生存率为68%,<12 cm H2O/L/s者为60%(p=0.58)。
  • 吸气阻力与C反应蛋白、铁蛋白、PaO2/FiO2比值及静态顺应性均无相关性。

证据类型、等级与局限

  • 证据类型:观察性队列(便利样本)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,COVID-19相关ARDS机械通气患者的吸气气道阻力正常至轻度升高,不依赖于阻塞性气道疾病史,不与疾病严重度生物标志物相关,也不能预测死亡。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: To measure inspiratory airflow resistance in patients with acute respiratory distress syndrome (ARDS) due to COVID-19.

DESIGN: Observational cohort of a convenience sample.

SETTING: Three community ICUs.

SUBJECTS: Fifty-five mechanically ventilated patients with COVID-19.

INTERVENTIONS: Measurements of ventilatory mechanics during volume control ventilation.

MEASUREMENTS: Flow-time and pressure-time scalars were used to measure inspiratory airways resistance.

RESULTS: The median inspiratory airflow resistance was 12 cm H2O/L/s (interquartile range, 10-16). Inspiratory resistance was not significantly different among patients with asthma or chronic obstructive pulmonary disease compared with those without a history of obstructive airways disease (median 12.5 vs 12 cm H2O/L/s, respectively; p = 0.66). Survival to 90 days among patients with inspiratory resistance above 12 cm H2O/L/s was 68% compared with 60% for patients below 12 cm H2O/L/s (p = 0.58). Inspiratory resistance did not correlate with C-reactive protein, ferritin, Pao2/Fio2 ratio, or static compliance.

CONCLUSIONS: Inspiratory airflow resistance was normal to slightly elevated among mechanically ventilated patients with ARDS due to COVID-19. Airways resistance was independent of a history of obstructive airways disease, did not correlate with biomarkers of disease severity, and did not predict mortality.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Nezami B, Tran HV, Zamora K, et al. Inspiratory Airway Resistance in Respiratory Failure Due to COVID-19. Crit Care Explor. 2022. PMID: 35506013. doi:10.1097/CCE.0000000000000669

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。